ASCO 2022 | Tucatinib & trastuzumab +/- chemo or pembrolizumab in unresectable or metastatic HER2+ GI cancers
HER2 gene amplification or overexpression frequently occurs in gastrointestinal malignancies, thus there is interest in the use of HER2-targeted therapies in this patient population. John H. Strickler, MD, Duke Cancer Institute, Durham, NC, talks on an ongoing Phase Ib/II, open-label dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Transcript (edited for clarity)
The combination of tucatinib and trastuzumab has already shown to be highly active in patients with HER2-positive colorectal cancer. One of the challenges we face is understanding when and how to use that therapy, whether it can combine with other therapies. That study explores that chemotherapy backbone, which is commonly used in colorectal cancer and also in gastric cancer, together with tucatinib and trastuzumab...
The combination of tucatinib and trastuzumab has already shown to be highly active in patients with HER2-positive colorectal cancer. One of the challenges we face is understanding when and how to use that therapy, whether it can combine with other therapies. That study explores that chemotherapy backbone, which is commonly used in colorectal cancer and also in gastric cancer, together with tucatinib and trastuzumab.
Read more...
